- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy ; volume:6 ; number:1 ; day:18 ; month:12 ; year:2018 ; pages:1-16 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (18.12.2018), 1-16, 12.2018
- Creator
-
Fromm, George
de Silva, Suresh
Johannes, Kellsey
Patel, Arpita
Hornblower, Josiah C.
Schreiber, Taylor H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0454-3
- URN
-
urn:nbn:de:101:1-2019020621525065139384
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fromm, George
- de Silva, Suresh
- Johannes, Kellsey
- Patel, Arpita
- Hornblower, Josiah C.
- Schreiber, Taylor H.
- SpringerLink (Online service)
Other Objects (12)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cancer immunotherapy beyond immune checkpoint inhibitors
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Immune checkpoint inhibitors for multiple myeloma immunotherapy
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
Cancer Immunotherapy of TLR4 Agonist–Antigen Constructs Enhanced with Pathogen‐Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD‐L1
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cancer immunotherapy beyond immune checkpoint inhibitors
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Immune checkpoint inhibitors for multiple myeloma immunotherapy
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
Cancer Immunotherapy of TLR4 Agonist–Antigen Constructs Enhanced with Pathogen‐Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD‐L1
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Cancer immunotherapy beyond immune checkpoint inhibitors
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Immune checkpoint inhibitors for multiple myeloma immunotherapy
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression